Outpatient Intravenous Insulin Treatment (Therapy)

CMS NCA document | source_status=Closed | review_type=New | public_comment_open=False | document_id=CAG-00410N

The Centers for Medicare and Medicaid Services (CMS) has determined the following. The evidence does not support a conclusion that outpatient intravenous insulin therapy improves health outcomes in Medicare beneficiaries. Therefore, CMS has determined that outpatient intravenous insulin therapy is not reasonable and necessary for any indication under section 1862(a)(1)(A) of the Social Security Act. Services comprising an Outpatient Intravenous Insulin Therapy regimen are nationally noncovered under Medicare when furnished pursuant to an outpatient intravenous insulin therapy regimen. Outpatient Intravenous Insulin Therapy (OIVIT) consists of an outpatient regimen of pulsatile or continuous intravenous infusion of insulin via any means, guided by the results of: measurement of respiratory quotient; and/or measurement of urine urea nitrogen (UUN); and/or measurement of arterial, venous or capillary glucose; and/or measurement of potassium concentration; performed in scheduled recurring intermittent episodes. This regimen is also sometimes termed Cellular Activation Therapy (CAT), Chronic Intermittent Intravenous Insulin Therapy (CIIIT), Hepatic Activation Therapy (HAT), Intercellular Activation Therapy (iCAT), Metabolic Activation Therapy® (MAT®), Pulsatile Intravenous Insulin Treatment (PIVIT), Pulse Insulin Therapy (PIT) and Pulsatile Therapy (PT) .